Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls?

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Introduction: The discovery of molecular biomarkers and the advent oftargeted therapies have led to a radical change in the treatment of severaltumors, including NSCLC. In the last few years, the number of molecularbiomarkers has rapidly increased, and a growing interest has been recentlyfocused on their potential prognostic and predictive value in clinical settings.Areas covered: This review describes all the molecular biomarkers with prognosticand predictive value in NSCLC, including both clinically approvedbiomarkers, and emerging biomarkers under investigation in clinical trials.Liquid biopsy and applications of circulating biomarkers are also described.Expert opinion: The oncological research is currently focusing on the discoveryand validation of molecular biomarkers in order to promote even morepersonalized treatment strategies. This paradigm of care will expand quicklythanks to the advent of new genotyping technologies, such as nextgenerationsequencing, making it possible to create a molecular-genomicprofile of every patient’s tumor. Liquid biopsy and the use of circulatingbiomarkersrepresent the new challenge of oncological research, with verypromising implications in the management of patients.
Original languageEnglish
Pages (from-to)1553-1566
Number of pages14
JournalExpert Opinion on Biological Therapy
Publication statusPublished - 2015

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls?'. Together they form a unique fingerprint.

Cite this